About Verseon
Verseon is a publicly listed company based in Fremont (United States) founded in 2002 by Eniko Fodor. Therapeutics are developed in oncology, ophthalmology, and cardiovascular areas. Verseon has raised $19.08 million across 7 funding rounds. The company has 60 employees. Verseon has completed 1 acquisition, including Edammo. Its focus areas include Diversified Pharmaceuticals. Its legal entity in India is Verseon India Private Limited (U73100TG2006PTC049464).
Company details
Verseon was founded in 2002 and is based in Fremont, United States, within the pharmaceutical sector. A drug discovery platform is utilized, relying on physics-based molecular modeling of protein-drug interactions and computational analysis to identify compounds for targets with known structures. The pipeline encompasses preclinical oral anticoagulants for anticoagulation, discovery-stage kallikrein inhibitors for diabetic macular edema, and angiogenesis inhibitors for solid tumors.
- Headquarters Fremont, United States
- Employees 60
- Founders Eniko Fodor
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website verseon.com
- Social LinkedIn X Facebook
- Legal Name Verseon India Private Limited
- Date of Incorporation 13 Mar, 2006
- Jurisdiction Hyderabad, Telangana, India
- Total Equity Funding$19.08M (USD)
in 7 rounds
- Latest Funding Round$101.4K (USD), Post-IPO
Apr 2019
- Employee Count60
- Investments & Acquisitions
Associated legal entities of Verseon
Verseon operates through Verseon India Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Verseon India Private Limited CIN U73100TG2006PTC049464 | Strike Off | 13 Mar 2006 | Hyderabad, Telangana | 2 | View details |
Funding Insights of Verseon
Verseon has successfully raised a total of $19.08M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $101.4 thousand completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.08M
- Total Rounds 7
- Last Round Post-IPO — $101,400
- First Round $6.49M
(Oct 2005)
All 7 funding rounds of Verseon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2019 | $101,400 | Post-IPO | – | – | – |
| May 2015 | $5.83M | Post-IPO | – | – | – |
| Nov 2014 | $451,000 | Series A | – | – | – |
| Jun 2011 | $69,827 | Series A | – | – | – |
| Sep 2010 | $259,573 | Series A | – | – | – |
| Sep 2009 | $11.81M | Series A | – | – | – |
| Oct 2005 | $6.49M | Series A | – | – | – |
Board of directors of Verseon India Private Limited (Verseon)
Verseon India Private Limited is the primary company behind Verseon. The board of Verseon India Private Limited currently have 2 directors; the longest-serving is Adityo Prakash, appointed in 2006. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Adityo Prakash DIN 00630969 | Director | 16 May 2006 | 20 yrs 5 mo | Verseon India Private Limited |
| Eniko Fodor Prakash DIN 00952147 | Director | 16 May 2006 | 20 yrs 5 mo | Verseon India Private Limited |
People of Verseon
11 people are tracked at Verseon (8 in leadership, 3 in team); the tracked headcount is 60.
| Name | Role | Group |
|---|---|---|
| Co-Founder & COO | Leadership | |
| Founder & CEO | Leadership | |
David Kita | Founder & VP of R&D | Leadership |
Anirban Datta | Senior Director of Discovery Biology | Leadership |
Walter Jones | Head Of Corporate Development | Leadership |
Ed Ratner | Head of Machine Learning Applications | Leadership |
David Williams | Senior Director of Platform Technology | Leadership |
Kevin Short | Head Of Chemistry | Leadership |
Brandon Warner | Data Scientist | Team |
Eric Chang | Principal Scientist | Team |
Lev Lev | Sr. Research Associate | Team |
Complete people profiles for Verseon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Verseon
Verseon has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Edammo.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Data analytics and consulting services are provided to clients. | edammoinc.com | Iowa, United States | 2016 | Oct 2022 | •••• |
Complete acquisition details for Verseon
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Verseon
5 dated milestones of Verseon across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Verseon is founded.
- Funding First funding round of $6.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $101K.
- Acquisition Acquires Edammo.
Web traffic of Verseon
The website of Verseon (verseon.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 13.9% vs previous month
Websites whose visitors overlap most with Verseon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| glassdoor.com | 100% | 30.5M | #1,976 | View details |
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Verseon (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Verseon
Complete news archive for Verseon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verseon
Verseon was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Verseon is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Verseon is a funded company, having raised a total of $19.08M across 7 funding rounds to date. The company's 1st funding round was a Series A of $6.49M, raised on Oct 2005.
Verseon has 60 employees.
Verseon was founded in 2002 and is based in Fremont, United States, within the pharmaceutical sector. A drug discovery platform is utilized, relying on physics-based molecular modeling of protein-drug interactions and computational analysis to identify compounds for targets with known structures. The pipeline encompasses preclinical oral anticoagulants for anticoagulation, discovery-stage kallikrein inhibitors for diabetic macular edema, and angiogenesis inhibitors for solid tumors.
Verseon has made 1 acquisition, including Edammo.
Verseon operates through Verseon India Private Limited.
The legal entities of Verseon currently have 2 directors, including Adityo Prakash, Eniko Fodor Prakash.